Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Scientific opinion on the possible risks posed by the influenza A (H3N2v) virus for animal health and its potential spread and implications for animal and human health
Swine are an important host in influenza virus ecology since they are susceptible to infections with both avian and human influenza A viruses.
Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016)
A consultation with European and international public health experts was convened to review data presented in newly conducted systematic reviews and meta-analyses regarding influenza antivirals, in order to develop an ECDC Expert Opinion.
Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA
This Expert Opinion outlines some pre-conditions that are considered to be essential at the national level prior to the use of new drugs for the treatment of tuberculosis, as well as specific conditions needed in order to successfully implement new TB drugs/regimens.